MRI Guided Focal Laser Ablation of Prostate Cancer
NCT: NCT03650595 · RECRUITING
Brief Summary
This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.
Frequently Asked Questions
What is MRI Guided Focal Laser Ablation of Prostate Cancer?
MRI Guided Focal Laser Ablation of Prostate Cancer is a clinical trial registered under NCT03650595. Current status: RECRUITING.
What is the status of NCT03650595?
The current status of NCT03650595 (MRI Guided Focal Laser Ablation of Prostate Cancer) is: RECRUITING.
When did MRI Guided Focal Laser Ablation of Prostate Cancer start?
MRI Guided Focal Laser Ablation of Prostate Cancer started on 2018-03-29.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.